LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced it has been added to the Russell Microcap Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. The inclusion in this widely followed benchmark is expected to increase the company's visibility among institutional investors and investment products that track Russell indexes, according to the company.
The milestone reflects progress under LIXTE's new leadership and strategic direction, supporting its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company originally focused on cancer drug development. Its lead compound, LB-100, is a first-in-class PP2A inhibitor that has shown tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has potential to enhance chemotherapies and immunotherapies. The company is conducting proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is also pioneering electronically controlled proton therapy systems for treating tumors. The proprietary LiGHT System is believed to offer advantages over existing proton therapy technologies. More information about Liora Technologies can be found at www.lioratechnologies.com.
The company's inclusion in the Russell Microcap Index marks a significant step in its transformation and could broaden its investor base. For further details, the full press release is available at https://ibn.fm/r6l81. The latest news and updates relating to LIXT can be found in the company's newsroom at https://ibn.fm/LIXT.
